Skip to main navigation Skip to search Skip to main content

Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease

  • Alessia Comes*
  • , Alyson W Wong
  • , Jolene H Fisher
  • , Julie Morisset
  • , Kerri A Johannson
  • , Erica Farrand
  • , Charlene D Fell
  • , Martin Kolb
  • , Hélène Manganas
  • , Gerard Cox
  • , Andrea S Gershon
  • , Andrew J Halayko
  • , Nathan Hambly
  • , Nasreen Khalil
  • , Mohsen Sadatsafavi
  • , Shane Shapera
  • , Teresa To
  • , Pearce G Wilcox
  • , Harold R Collard
  • , Christopher J Ryerson
  • *Corresponding author
  • University of Montreal
  • University of California at San Francisco
  • McMaster University
  • University of British Columbia
  • University of Toronto

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Mortality risk assessment in interstitial lung disease (ILD) is challenging. Our objective was to determine the prognostic significance of BMI and change in weight in the most common fibrotic ILD subtypes.RESEARCH QUESTION: Could BMI and weight loss over time be reliable prognostic indicators in patients with fibrotic ILD?STUDY DESIGN AND METHODS: This observational retrospective multicenter cohort study enrolled patients with fibrotic ILD from the six-center CAnadian REgistry for Pulmonary Fibrosis (CARE-PF, derivation) and the ILD registry at the University of California, San Francisco (UCSF, validation). Patients were subcategorized as underweight (BMI < 18.5), normal weight (BMI > 18.5-24.9), overweight (BMI 25-29.9), or obese (BMI > 30). Annual change in weight was calculated for all years of follow-up as the slope of best fit using the least square method based on every available measurement. Separate multivariable analyses evaluated the associations of BMI and change in weight with mortality, adjusting for common prognostic variables.RESULTS: The derivation and validation cohorts included 1,786 and 1,779 patients, respectively. Compared with patients with normal BMI, mortality was highest in patients who were underweight (hazard ratio [HR], 3.19; 95% CI, 1.88-5.43; P < .001) and was lowest in those who were overweight (HR, 0.52; 95% CI, 0.36-0.75; P < .001) or obese (HR, 0.55; 95%CI, 0.37-0.83; P < .001) in the analysis adjusted for the ILD-GAP (gender, age, physiology) Index. Patients who had a weight loss of at least 2 kg within 1 year had increased risk of death in the subsequent year (HR, 1.41; 95% CI, 1.01-1.97; P = .04) after adjustment for the ILD-GAP Index and baseline BMI category, with a plateau in risk for patients with greater weight loss. Consistent results were observed in the validation cohort.INTERPRETATION: Both BMI and weight loss are independently associated with 1-year mortality in fibrotic ILD. BMI and weight loss may be clinically useful prognostic indicators in fibrotic ILD.
Original languageEnglish
Pages (from-to)1320-1329
Number of pages10
JournalChest
Volume161
Issue number5
DOIs
Publication statusPublished - 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Keywords

  • BMI
  • change in weight
  • idiopathic pulmonary fibrosis
  • interstitial lung disease
  • prognosis

Fingerprint

Dive into the research topics of 'Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease'. Together they form a unique fingerprint.

Cite this